Halozyme Therapeutics Inc. HALO

NAS: HALO | ISIN: US40637H1095   19/04/2024
38,64 USD (+2,20%)
(+2,20%)   19/04/2024

27 februari 2024 · Halozyme to Participate in Upcoming Investor Conferences · Persbericht

20 februari 2024 · Halozyme Reports Fourth Quarter And Full Year 2023 Financial And Operating Results · Persbericht

8 februari 2024 · Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results · Persbericht

29 januari 2024 · Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Persbericht

18 januari 2024 · Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis · Persbericht

16 januari 2024 · Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Persbericht

16 januari 2024 · Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types · Persbericht

12 januari 2024 · Halozyme to Host Investor Business Forum and Long-Term Outlook Call · Persbericht

6 november 2023 · Halozyme Reports Third Quarter 2023 Financial And Operating Results · Persbericht

6 november 2023 · Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease · Persbericht

30 oktober 2023 · Halozyme To Report Third Quarter 2023 Financial and Operating Results · Persbericht

19 oktober 2023 · Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Persbericht

16 oktober 2023 · Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference · Persbericht

16 oktober 2023 · Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery · Persbericht

31 augustus 2023 · Halozyme to Present at Upcoming Investor Conferences · Persbericht

29 augustus 2023 · Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain · Persbericht

8 augustus 2023 · Halozyme Reports Second Quarter 2023 Financial And Operating Results · Persbericht

25 juli 2023 · Halozyme To Report Second Quarter 2023 Financial and Operating Results · Persbericht

17 juli 2023 · Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy · Persbericht

13 juli 2023 · Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis · Persbericht

Mijn selecties